- 商品介绍
- 规格参数
- 包装参数
Application
Levosimendan has been used for screening its anti-human immunodeficiency virus type 1 (HIV-1) property. It has also been used for screening its cytotoxic effects in TP53 mutant and wild-type lung adenocarcinoma cell lines
Biochem/physiol Actions
Levosimendan has a potential to inhibit both acute human immunodeficiency virus type 1 (HIV-1) replication and the reactivation of latent HIV-1 proviruses. Therefore, it is considered to be a promising anti-HIV-1 agent.
Levosimendan is a calcium sensitiser.
Levosimendan is a calcium sensitiser. The compound increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan binds to cardiac troponin C in a calcium-dependent manner and stabilizes troponin C. This is followed by actin-myosin cross-bridges, without increasing myocardial consumption of ATP. Additionally the compound acts as vasodilator by opening an ATP-sensitive potassium channels. Levosimendan is a drug used for treatment of congestive heart failure. Also it can be used to treat calcium channel blocker overdose.
| Quality Level | 100 |
| assay | ≥98% (HPLC) |
| form | powder |
| optical activity | [α]/D -500 to -650°, c = 0.5 in THF |
| color | yellow |
| solubility | DMSO: ≥20 mg/mL |
| storage temp. | room temp |
| SMILES string | C[C@@H]1CC(=O)NN=C1c2ccc(N\N=C(\C#N)C#N)cc2 |
| InChI | 1S/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)/t9-/m1/s1 |
| InChI key | WHXMKTBCFHIYNQ-SECBINFHSA-N |
| Gene Information | human ... PDE3A(5139), PDE3B(5140), TNNC1(7134), TNNI3(7137), TNNT2(7139) |
| 长度(mm) | |
| 宽度(mm) | |
| 高度(mm) | |
| 重量(kg) |
-
¥ 2528.88
-
询价
-
¥ 2814.26
-
¥ 3109.49
-
¥ 8293.41
-
询价
-
询价
-
询价
-
询价
-
询价
-
询价
-
询价
-
询价
-
¥ 3442.25
-
¥ 9737.84
-
¥ 4968.78
-
¥ 6330.00
-
询价
-
¥ 3335.66
-
¥ 2842.54
微信小程序
7X24小时在线咨询